IRIS Accounts Production v23.3.1.45 08112587 director 1.7.22 30.6.23 30.6.23 0 0 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh081125872022-06-30081125872023-06-30081125872022-07-012023-06-30081125872021-06-30081125872021-07-012022-06-30081125872022-06-3008112587ns10:Originalns15:EnglandWales2022-07-012023-06-3008112587ns14:PoundSterlingns10:Original2022-07-012023-06-3008112587ns10:Originalns10:Director12022-07-012023-06-3008112587ns10:Original2022-07-012023-06-3008112587ns10:Original2023-06-3008112587ns10:Originalns10:PrivateLimitedCompanyLtd2022-07-012023-06-3008112587ns10:Originalns10:SmallEntities2022-07-012023-06-3008112587ns10:Originalns10:AuditExempt-NoAccountantsReport2022-07-012023-06-3008112587ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3008112587ns10:SmallCompaniesRegimeForAccountsns10:Original2022-07-012023-06-3008112587ns10:Originalns10:AbridgedAccounts2022-07-012023-06-3008112587ns10:Original2021-07-012022-06-3008112587ns10:Originalns10:OrdinaryShareClass12022-07-012023-06-3008112587ns10:Originalns10:RegisteredOffice2022-07-012023-06-3008112587ns10:Original2022-06-3008112587ns10:Originalns5:CurrentFinancialInstruments2023-06-3008112587ns10:Originalns5:CurrentFinancialInstruments2022-06-3008112587ns5:ShareCapitalns10:Original2023-06-3008112587ns5:ShareCapitalns10:Original2022-06-3008112587ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-06-3008112587ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-06-3008112587ns10:Originalns5:ComputerEquipment2022-07-012023-06-3008112587ns10:Original2022-06-3008112587ns10:Originalns10:OrdinaryShareClass12023-06-30
REGISTERED NUMBER: 08112587 (England and Wales)
















Unaudited Financial Statements for the Year Ended 30 June 2023

for

Clinical And Biomedical Computing
Consultants Limited

Clinical And Biomedical Computing
Consultants Limited (Registered number: 08112587)






Contents of the Financial Statements
for the Year Ended 30 June 2023




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 4


Clinical And Biomedical Computing
Consultants Limited

Company Information
for the Year Ended 30 June 2023







DIRECTOR: Dr J Rashbass





REGISTERED OFFICE: Kemp House
160 City Road
London
EC1V 2NX





REGISTERED NUMBER: 08112587 (England and Wales)





ACCOUNTANTS: Hardcastle Burton LLP
Lake House
Market Hill
Royston
Hertfordshire
SG8 9JN

Clinical And Biomedical Computing
Consultants Limited (Registered number: 08112587)

Abridged Balance Sheet
30 June 2023

30.6.23 30.6.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 3,464 5,910

CURRENT ASSETS
Debtors 3,704 3,640
Cash at bank and in hand 16,358 24,154
20,062 27,794
CREDITORS
Amounts falling due within one year 10,888 9,158
NET CURRENT ASSETS 9,174 18,636
TOTAL ASSETS LESS CURRENT
LIABILITIES

12,638

24,546

PROVISIONS FOR LIABILITIES 658 1,122
NET ASSETS 11,980 23,424

CAPITAL AND RESERVES
Called up share capital 5 1 1
Retained earnings 11,979 23,423
SHAREHOLDERS' FUNDS 11,980 23,424

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Clinical And Biomedical Computing
Consultants Limited (Registered number: 08112587)

Abridged Balance Sheet - continued
30 June 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 30 June 2023 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 28 November 2023 and were signed by:





Dr J Rashbass - Director


Clinical And Biomedical Computing
Consultants Limited (Registered number: 08112587)

Notes to the Financial Statements
for the Year Ended 30 June 2023

1. STATUTORY INFORMATION

Clinical And Biomedical Computing Consultants Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 33% on cost

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Basic financial assets
Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities
Basic financial liabilities, including creditors and loans that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Clinical And Biomedical Computing
Consultants Limited (Registered number: 08112587)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2023

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 July 2022 14,487
Additions 1,177
Disposals (4,640 )
At 30 June 2023 11,024
DEPRECIATION
At 1 July 2022 8,577
Charge for year 3,623
Eliminated on disposal (4,640 )
At 30 June 2023 7,560
NET BOOK VALUE
At 30 June 2023 3,464
At 30 June 2022 5,910

5. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.6.23 30.6.22
value: £    £   
1 Ordinary £1 1 1